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increased 161.8%, and any oxycodone-containing compound
increased 267.3%. Mentions of each of these three classes of
opioids remained less than 2% of all total drug mentions per
year for each year studied. Medical use of the selected opioid
classes, as reported in the ARCOS database and measured by
grams distributed, all increased substantially (fentanyl 151.2%,
morphine 48.8%, oxycodone 347.9%). CONCLUSIONS: Using
this method of analysis, the rates of drug abuse, and resultant
morbidity secondary to the use of opioid analgesics, remains low
in spite of the increase in medical use of these substances.
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Secondary analysis of the Medical Expenditure Panel Survey
(MEPS) from 1996 to 1999. OBJECTIVE: To examine patterns
in opioid use in 1996, 1997, 1998 and 1999 among individuals
with back pain in the US, and to investigate trends in the use of
overall and individual opioid category. No study has examined
at a national level the patterns and trends of opioid use among
individuals with back pain. METHODS: Individuals with back
pain were stratiﬁed by socio-demographic characteristics and
geographical regions. Rates of overall opioid use were compared
among different strata. To investigate trends in opioid use, use
rates of the overall and individual opioid category were calcu-
lated and compared. From 1996 to 1999, the use of opioid was
not signiﬁcantly different across different gender or racial/ethni-
cal groups, but signiﬁcantly higher among individuals who were
publicly insured, had low or below low income and had educa-
tion at or below 12th grade compared to their respective coun-
terparts. During the 4-year period, signiﬁcant variations in
opioid use across different age groups or geographic regions 
were observed in early years. But the variations became non-
signiﬁcant in later years. RESULTS: Trend analysis indicated that
the rates of overall opioid use increased slightly across the 4-year
span. Among individual opioid categories, the use of oxycodone
or hydrocodone increased whereas the use of propoxyphene
decreased. CONCLUSIONS: The signiﬁcantly higher use of
opioids among individuals who were publicly insured, had low
or below low income and had education at or below 12th grade
raised serious concerns about drug safety in this patient popula-
tion. The increase in the use of hydrocodone and oxycodone
indicated a need to better assess the efﬁcacy and safety associ-
ated with these drugs among individuals with back pain.
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Secondary analysis of the 2000 Medical Expenditure Panel
Survey (MEPS). OBJECTIVE: To examine national prescription
patterns of non-steroidal anti-inﬂammatory drugs (NSAIDs) and
muscle relaxants among individuals with back pain in the United
States. Summary of Background Data. There is a lack of infor-
mation on national prescription patterns of NSAIDs and muscle
relaxants among individuals with back pain in the US.
METHODS: Traditional NSAIDs, cyclooxygenase-2-speciﬁc
(COX-2) inhibitors and muscle relaxants were investigated. Indi-
viduals with back pain were stratiﬁed by socio-demographic
characteristics and geographical regions. For each medication
category, overall prescribing frequency was compared across dif-
ferent strata and individual drug prescription was analyzed.
RESULTS: Traditional NSAIDs, COX-2 inhibitors and muscle
relaxants respectively accounted for 16.3%, 10% and 18.5% of
total prescriptions for back pain in 2000. Among individual
drugs, ibuprofen and naproxen accounted for most of the pre-
scriptions for traditional NSAIDs (60%), whereas two-thirds 
of the prescriptions for muscle relaxants were attributable to
cyclobenzaprine, carisoprodol and methocarbamol. Prescription
of COX-2 inhibitors or muscle relaxants demonstrated wide
variations across different regions. Several individual character-
istics including age, race and educational level were associated
with the prescription of some of the medications. CONCLU-
SIONS: Neither traditional NSAIDs, nor COX-2 inhibitors, 
nor muscle relaxants dominated prescriptions for back pain.
However, a small number of individual drugs were attributable
to most of the prescriptions for traditional NSAIDs or muscle
relaxants. The prescription of some of the medications demon-
strated wide variations across different regions or different racial
and educational groups. More studies are needed to understand
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OBJECTIVES: To illustrate how use of generalized linear models
to analyze health care cost data may provide a better distribu-
tional ﬁt than commonly employed approaches (e.g., linear or
log-linear ordinary least squares [OLS] regression), and could
yield quantitatively and inferentially different conclusions.
METHODS: Data were obtained from the PharMetrics Patient-
Centric Database, which includes integrated medical pharmacy
claims from 73 health plans nationwide. Patients with a diag-
nosis of intermittent claudication (ICD-9-CM 443.9x) who
newly started cilostazol or pentoxifylline therapy between June
1999–March 2002 were selected for analysis. Six-month pre-
treatment and follow-up periods were created in relation to the
ﬁrst observed prescription. Total costs of care during follow-up
were estimated based on health plan payments for medications
and services rendered, and were expressed in 2002 U.S. dollars.
Alternative multivariate approaches to analyzing total costs were
employed–an OLS model (log-linear) versus a generalized linear
model (GLM) with a log-link function and a gamma distribu-
tion. Covariates included demographic and other baseline/
pretreatment variables. Histograms of untransformed and log-
transformed costs were compared to gamma and normal distri-
butions; goodness-of-ﬁt assessments also were conducted. The
results of OLS (on a log-transformed outcome) and gamma GLM
models were compared. RESULTS: Analyses were conducted for
763 and 506 patients newly starting cilostazol and pentoxifylline
therapy respectively. The results of goodness-of-ﬁt testing
(deviance: 1489.5 vs. 1366.4 for degrees of freedom = 1,255)
indicated that the gamma GLM model approximated the cost
distribution most closely. Observed annual mean total costs were
$6238 and $5568 for cilostazol and pentoxifylline respectively;
application of the two models yielded different results—a non-
signﬁcant (p = 0.0620) treatment effect using log-linear OLS, and
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signiﬁcantly (p = 0.0432) higher costs for cilostazol using a
gamma GLM model. CONCLUSIONS: The gamma GLM tech-
nique is a powerful tool for modeling strictly positive skewed
outcomes and should be more widely employed in pharma-
coeconomic analyses.
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To design a cost-effectiveness trial, the Delta-K method newly
developed provides us with a new formula for sample-size 
calculation. The Delta-K utilizes the difference between two 
cost-effectiveness ratios, qA and qB, respectively of control and
experimental regimens (i.e., KD = 1/qA - 1/qB). The advantage of
the method is simplicity for estimating the sample-size, naturally
extending the conventional binomial formula, whereas under the
assumption of “econstant” cost for each regimen. OBJECTIVES:
Using multivariate analysis with the Monte-Carlo simulation for
“evariable” costs, we assess the robustness of the Delta-K
method in search of the probable range of sample-sizes calcu-
lated based on the formula. METHOD: A case study of cost-
consequence analysis is employed to validate the design of a
clinical trial, which evaluates herpes zoster treatment with
Valaciclovir vs. Aciclovir. Our former investigation on this case
illuminated that the sample-size for the RCT could be reduced
from n = 821 to n = 36 in use of the Delta-K method regarding
the average costs as constant. In the Monte-Carlo simulation,
therefore, the three major factors of costs such as primary med-
ication, treatment for post herpes neuralgia (PHN), and outpa-
tient care were assumed to have a normal distribution since each
factor is quantiﬁed with the mean and the standard deviation
(S.D.)(e.g., for PHN; US$1504.9 ± 6.1 in Valaciclovir, whereas
US$2006.6 ± 6.6 in Aciclovir). Under these conditions Monte-
Carlo simulation was run up to 10,000 times to assess the overall
distribution of sample-sizes calculated from the formula.
RESULTS: The runs of 10,000 times resulted in the distribution
with the sample-size of 35.2 ± 0.8(the mean ± 2S.D.) and the
range of (33.7, 37.0) = (min, max), which is far smaller than the
original sample-size n = 821. CONCLUSION: We conﬁrmed suf-
ﬁcient robustness of the Delta-K method in a case study even if
medical costs vary against the assumption of constant cost. It
suggests the usefulness of the new method.
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The concept of incremental cost effectiveness ratios (ICERs) and
conﬁdence intervals (CIs) may seem complicated to many prac-
titioners and decision makers. There is a growing body of liter-
ature regarding the use of NNT (number needed to treat) as a
statistic that may be easier to understand in clinical practice.
NNTs and ICERs are receiving increased attention in the 
interface of clinical and economic concepts. OBJECTIVE: To
compare the ICER and CI results by using NNT-related calcula-
tions versus bootstrap analyses utilizing datasets from three pub-
lished papers. METHODS: An NNT spreadsheet calculator was
developed that generates NNT conﬁdence intervals and incre-
mental cost to treat calculations. Datasets with an aggregate total
of over 2000 patients from three previously published pharma-
coeconomic studies were analyzed with both the NNT and boot-
strap ICER approach. The NNT calculator used a two by two
contingency table with additional cells for including cost of each
treatment. Conﬁdence intervals (95%) were calculated for NNT
and the upper and lower values of the incremental cost per suc-
cessfully treated patient. In contrast, the bootstrap software uti-
lizes each individual patient case in the datasets to generate ICER
ratios and ICER conﬁdence intervals. RESULTS: The NNT
results for the mean cost needed to treat for one successful
outcome showed good agreement with the bootstrap generated
ICER slopes. For NNT versus bootstrap, the anti-platelet study
mean ICERs were $43,729 vs. $43,742, the antidepressant 
comparative study ICERs were -$1648 vs. -$1647 and the 
antidepressant combination study ICERs were -$188,014 vs. 
-$188,012. Using 5th and 95th percentiles for cost of treatment
multiplied by corresponding NNT conﬁdence intervals did not
generate very close agreement with the bootstrapped CIs. CON-
CLUSIONS: NNT related calculations may be a method for ini-
tially analyzing local pilot data or explore the economic
ramiﬁcations of a clinical publication when the full dataset is not
available.
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OBJECTIVES: Cause and effect diagrams (also known as
Ishikawa or ﬁshbone diagrams) graphically depict the relation-
ships between a particular outcome and all of the identiﬁed
factors contributing to that outcome. The diagram’s structure
includes a central “bone” with the topic of interest (the “head”)
attached at the right-hand end. Branching out from the central
line are “sub-bones” that represent primary causal factors, and
each of these in turn has sub-bones representing subsidiary con-
tributing factors. METHODS: Ishikawa diagrams were origi-
nally developed and have typically been used as a tool for root
cause analyses, but they also can beneﬁt the planning of eco-
nomic analyses for a particular disease state, medical technology,
or other health care intervention. Recent projects conducted by
the Department of Health Policy of Jefferson Medical College
illustrate the value of Ishikawa diagrams in planning economic
analyses. One project involved the development of an economic
model related to the diagnosis and management of Crohn’s
disease. An Ishikawa diagram was used to organize the ﬁndings
of an extensive literature review on this topic. The main cate-
gories, or “sub-bones” contributing to the cost of Crohn’s
included: diagnostic work-up, medication therapy, administra-
tion, hospitalization, surgery, and adverse reactions/complica-
tions. RESULTS: Many of these categories were further broken
down into appropriate subcategories. In another project, this
tool was used to organize and graphically depict cost factors for
allogeneic blood transfusions. Identiﬁed factors contributing to
total costs were organized around four main sub-bones: Acqui-
sition, Administration, Preparation, and Adverse Events/Com-
plications. CONCLUSIONS: In both of these projects, the
constructed diagram facilitated the organization of large
amounts of information, selection of key factors for inclusion in
decision analytic economic models, and identiﬁcation of unmea-
sured contributors to cost, which might inﬂuence the model’s
assumptions or ﬁndings. Outcomes researchers therefore are
